---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-047832"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T15:13:57.034365+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rezolute Q3 net loss $18.9M; sunRIZE enrollment on track, BTD for ersodetug

## Summary
- Cash $88.4M at March 31, 2025, down from $127.1M at June 30, 2024.
- Phase 3 sunRIZE study enrollment expected to complete May 2025; topline results anticipated December 2025.
- FDA granted Breakthrough Therapy Designation to ersodetug for tumor hyperinsulinism hypoglycemia in May 2025.
- April 2025 underwritten offering raised ~$97M, extending cash runway to mid-2027.
- Appointed Erik Harris (Ultragenyx CCO) to Board of Directors in March 2025.

## SEC filing metadata
- accession: 0001104659-25-047832
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/0001104659-25-047832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/tm2514822d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-047832
- JSON: https://secwatch.observer/filing/0001104659-25-047832.json
- Plain text: https://secwatch.observer/filing/0001104659-25-047832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.